Skip to main content

Table 2 Clinical trials of CD47/SIRPα-targeted bispecific antibodies in hematological malignancies

From: Targeting macrophages in hematological malignancies: recent advances and future directions

Name

Initial time of clinical studies

phase

Type of tumors

ClinicalTrials.gov Identifier

Outcome measures

TG-1801 (NI-1701)

2021.4

Phase IB

B-cell lymphoma or CLL

NCT04806035

To determine the recommended phase II dose (RP2D), ORR

IMM0306

2021.8

Phase I

R/R CD20-positive B-NHL

NCT04746131

Maximum Tolerated Dose (MTD) of IMM0306 as measured by incidence of DLTs (Dose Limiting Toxicity)

IBI-322

2021.5

Phase I

Hematological malignancies

NCT04795128

treatment related AEs, ORR

IBI-322

2021.12

Phase IA/IB

Myeloid Tumor

NCT05148442

Treatment related AEs, ORR

DSP107

2021.9

Phase IB/II

MDS, AML and T-cell lymphoproliferative disease

NCT04937166

Treatment related AEs, Dose Limiting Toxicities (DLT), ORR, MRD

HX009

2021.12

Phase I/II

R/R-lymphoma

NCT05189093

Treatment related AEs, ORR, PFS, DOR, DCR, PK/PC

JMT601 (CPO107)

2021.12

Phase I/II

Advanced CD20-positive NHL

NCT04853329

To determine the recommended single-agent CPO107 RP2D, safety, efficacy

SG2501

2022.4

Phase IA/IB

R/R hematological malignancies and lymphoma

NCT05293912

To evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy